Interviews

Scarlett Lin Gomez, PhD, MPH, of UCSF, explains why Asian American women's breast cancer survival advantage persists after adjusting for clinical and lifestyle factors.

Cox and Abbadi outline next steps for BDNF/TrkB-targeted therapy, including translating the approach to high-grade serous ovarian cancer.

Hearn Jay Cho, MD, PhD, discusses the ongoing role of the CoMMpass dataset in researching immunotherapy and targeted therapy in high-risk multiple myeloma.

Maureen Cox, PhD, and Jumana Abbadi, MD, explain how macrophage-derived BDNF drives sensory nerve growth into triple-negative breast tumors, a potential drug target.

Learn how community oncologists deliver bispecific antibodies safely: step-up dosing, CRS prevention, infection support, and patient counseling.

Cancer centers face rising outpatient demand; learn how smarter scheduling, better data, and AI-driven capacity planning ease flow, staffing strain, and complex therapy coordination.

Hearn Jay Cho, MD, PhD, of the Multiple Myeloma Research Foundation, looks back on 15 years of the groundbreaking CoMMpass genomic study.

Postprogression access to effective therapy was linked to smaller OS benefits in targeted therapy trials but not immunotherapy trials, an analysis found.

Sagar Lonial, MD, discusses the importance of baseline MRD assessment to aid in using sustained MRD negativity for eventual discontinuation of lenalidomide in newly diagnosed multiple myeloma.

City of Hope's Dr Ravi Salgia urges fellow oncologists to refer eligible patients to a new national trial predicting immunotherapy success in NSCLC.

Ravi Salgia, MD, PhD, explains the goals of IMMUNO-BIOMAP, a phase 2 trial identifying biomarkers to predict immunotherapy response in NSCLC.

City of Hope's Dr Ravi Salgia on what it would truly take to cure stage IV non–small cell lung cancer and where oncology is headed next in the years ahead.

Sagar Lonial, MD, discusses why to take an individualized approach despite the trial's findings supporting discontinuation of lenalidomide at 2 years.

Benjamin Herzberg, MD, discusses unmet needs, immunotherapy sequencing, and referral timing in KRAS-mutant NSCLC.

ASCO 2026 data show ePRO remote symptom monitoring cuts ER visits and costs, enabling faster toxicity detection and safer community cancer care.

OncoPRO unites oncology practices to streamline ePRO remote symptom monitoring, improving enrollment, workflow integration, and change management through shared implementation strategies.

ASCO 2026 data show ePRO symptom tracking keeps cancer patients on therapy longer, cuts hospitalizations and costs, and may boost survival.

City of Hope's Dr Ravi Salgia explains a new national trial using biomarkers to predict immunotherapy success in advanced non–small cell lung cancer.

Real-world ASCO 2026 data show ePRO-based remote monitoring helps catch metastatic cancer treatment symptoms earlier, improving toxicity control and reducing hospitalizations.

Five-year SENOMAC trial results show omitting completion axillary dissection preserves survival and significantly reduces arm morbidity, says Jana de Boniface, MD, PhD.

ASCO 2026 real-world data tie GLP-1 drugs to longer cancer survival, but oncology EHRs miss timing and duration—heres why it matters.

Mark Agulnik, MD, discusses the trend away from surgery and toward targeted treatment of progressive desmoid tumors, and how sequencing is the next major question.

Real-world community oncology data link GLP-1 drugs to 34% lower death risk across cancers, prompting calls for prospective trials.

Javier Cortés, MD, PhD, discusses the final KEYNOTE-522 analysis, showing pembrolizumab plus chemotherapy sustains long-term survival benefit in early-stage TNBC.

Samantha Watters, PhD, MPH, discusses the most notable findings about the link connecting social vulnerability, physician access, and unmet need for allogeneic stem cell transplant.

A cross-sectional analysis of 52 first-line trials found post-progression access to effective therapy correlated with OS benefit in targeted therapy but not checkpoint blockade.

Vincent Ma, MD, describes his initial reaction to the July 30, 2026, FDA advisory committee vote on RP1 plus nivolumab in advanced melanoma.

Damon R. Reed, MD, compared the carefully-considered off-label use of trastuzumab deruxtecan with a clinical trial experience in 2 rare sarcoma subtypes.

Sara Hurvitz, MD, discusses VIKTORIA-1 data on gedatolisib in PIK3CA-mutant HR+/HER2- breast cancer, following the drug's recent FDA approval.

Samantha E. Watters, PhD, MPH, discusses the variables she examined in her research on US states at risk of unmet needs in allogeneic transplant access.